Seer (SEER) Total Non-Current Liabilities (2020 - 2026)
Seer (SEER) posted quarterly Total Non-Current Liabilities of $30.6 million for Q1 2026, down 15.45% year-over-year from $36.2 million in Q1 2025, and down 16.7% quarter-over-quarter from $36.8 million in Q4 2025.
Analysis
Seer (SEER) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Seer's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $30.6 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 15.45% year-over-year to $30.6 million; the TTM figure through Mar 2026 stood at $30.6 million (down 15.45% YoY), while the FY2025 annual figure was $36.8 million, down 5.67% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $30.6 million, down from $36.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $43.9 million in Q2 2022, with the low at $30.6 million in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $39.0 million (2023), against an average of $38.8 million.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 334.12% in 2022, then decreased 18.37% in 2025.
- Seer's Total Non-Current Liabilities stood at $40.6 million in 2022, then slipped by 3.52% to $39.2 million in 2023, then decreased by 0.53% to $39.0 million in 2024, then dropped by 5.67% to $36.8 million in 2025, then declined by 16.7% to $30.6 million in 2026.
- Business Quant data shows SEER's Total Non-Current Liabilities at $30.6 million in Q1 2026, $36.8 million in Q4 2025, and $36.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Seer | 107.57 Mn | 107.57 Mn | 1.51 Mn | 30.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30.94 Mn |
| Mar 31, 2026 | 30.63 Mn |
| Dec 31, 2025 | 36.77 Mn |
| Sep 30, 2025 | 36.78 Mn |
| Jun 30, 2025 | 34.18 Mn |
| Mar 31, 2025 | 36.22 Mn |
| Dec 31, 2024 | 38.98 Mn |
| Sep 30, 2024 | 38.63 Mn |
| Jun 30, 2024 | 41.87 Mn |
| Mar 31, 2024 | 38.23 Mn |
| Dec 31, 2023 | 39.19 Mn |
| Sep 30, 2023 | 39.02 Mn |
| Jun 30, 2023 | 42.90 Mn |
| Mar 31, 2023 | 39.44 Mn |
| Dec 31, 2022 | 40.62 Mn |
| Sep 30, 2022 | 42.13 Mn |
| Jun 30, 2022 | 43.93 Mn |
| Mar 31, 2022 | 40.29 Mn |
| Dec 31, 2021 | 35.88 Mn |
| Sep 30, 2021 | 12.24 Mn |